Ionogen, LLC – FDA Warning Letter, Jun 23, 2020
On July 7, 2020, the FDA issued a Warning Letter to the company operating ionopure.com after reviewing their website on June 23, 2020. The FDA observed that "Ionopure Skin & Hands" was offered for sale with claims indicating its intent to mitigate, prevent, treat, diagnose, or cure COVID-19.
The FDA determined this product is an unapproved new drug, violating section 505(a) of the FD&C Act (21 U.S.C. § 355(a)), and a misbranded drug under section 502 of the FD&C Act (21 U.S.C. § 352). Its introduction into interstate commerce is prohibited by sections 301(a) and (d) of the FD&C Act (21 U.S.C. § 331(a) and (d)).
The letter emphasizes the public health emergency declared for COVID-19 and the FDA's urgent measures against unapproved products making COVID-19 claims. The company was instructed to immediately cease selling the unapproved and unauthorized product for COVID-19-related uses.
The company must email COVID-19-Task-Force-CDER@fda.hhs.gov within 48 hours, detailing corrective actions, steps to prevent recurrence, and supporting documentation.
ID · 4e700ca2-1c26-4dd6-a694-6de1bda0565a
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.